Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone…

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the U.S. Food and Drug Administration (“FDA“) has accepted for filing the Company’s previously-announced New Drug Application (“NDA”) seeking authorization to market (more…)

Intellipharmaceutics Submits New Drug Application for Rexista … – Nasdaq


TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA“) seeking authorization to market its Rexista® (more…)

FDA approves oxycodone hydrochloride and naltrexone hydrochloride ER capsules CII with…

FDA has approved oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER—Pfizer) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, long-term opioid treatment. The drug is the only oxycodone with oral abuse-deterrent features described in the labeling.

FDA has approved oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER—Pfizer) extended-release capsules, for oral use, CII for the (more…)